The Abivax bowel disease drug trial has produced encouraging late-stage results, bringing the French biotechnology company one step closer to introducing a potential new treatment for ulcerative colitis. The company announced that its investigational drug, obefazimod, met all primary and key secondary endpoints in a pivotal Phase 3 study, demonstrating strong and sustained remission rates among patients with moderate-to-severe disease.
However, reports of a small number of cancer cases during the study have also raised concerns about the drug’s long-term safety profile. Despite those concerns, experts say the efficacy results could make Abivax’s obefazimod drug a significant new option for people living with inflammatory bowel disease (IBD).
What Makes Abivax’s Obefazimod Medicine Different?
The Abivax bowel disease drug trial focuses on obefazimod, a unique therapy designed to enhance miR-124, a naturally occurring regulator of inflammation.
Unlike many existing treatments that require injections or infusions, obefazimod is an oral bowel disease medication taken once daily.
The company describes it as a potential first-in-class ulcerative colitis drug, meaning it works through a mechanism that differs from currently approved therapies such as biologics and JAK inhibitors.
This combination of convenience and efficacy could help address ongoing challenges faced by bowel disease patients who require long-term disease management.
Abivax Bowel Disease Drug Trial Achieves Primary Goal
According to the official release, the Abivax bowel disease drug trial evaluated obefazimod in Phase 3. The ABTECT maintenance trial, a global, randomized, double-blind, placebo-controlled study involving 580 adults with moderately to severely active ulcerative colitis.
Participants who responded to earlier induction studies were assigned to receive either 25 mg or 50 mg of obefazimod once daily or a placebo over 44 weeks.
The results of Abivax’s obefazimod drug trial showed:
- 50.8% clinical remission rate in the 25 mg group
- 51.3% clinical remission rate in the 50 mg group
- 10.4% clinical remission rate in the placebo group
Both treatment groups achieved statistically significant improvements compared with placebo, meeting the study’s primary endpoint.
Marc de Garidel, Chief Executive Officer of Abivax, described the findings as a major milestone. “Today’s landmark Phase 3 results highlight the exceptional potential of obefazimod to redefine the treatment landscape for ulcerative colitis,” he said.
Strong Secondary Outcomes Support Long-Term Benefits
Beyond clinical remission, the Abivax bowel disease drug trial demonstrated meaningful improvements across several additional measures used to evaluate disease control.
Patients receiving the Abivax ulcerative colitis drug achieved higher rates of:
- Endoscopic improvement
- Endoscopic remission
- Histologic-endoscopic mucosal improvement (HEMI)
- Corticosteroid-free clinical remission
- Sustained clinical remission
These measures indicate not only symptom relief but also healing of the intestinal lining, which can reduce complications and improve long-term outcomes.
The strong performance across multiple endpoints has positioned the obefazimod Phase 3 trial among the most closely watched developments in ulcerative colitis treatment.
Safety Data Draws Attention Despite Positive Results
While the overall Abivax clinical trial results were positive, investors reacted cautiously after the company disclosed several cancer-related events during the study.
The safety analysis reported:
- One case of prostate cancer
- One case of breast cancer
- One case of colonic dysplasia
- Four cases of non-melanoma skin cancer in the higher-dose group
Abivax stated that investigators found no evidence linking the prostate, breast, or colon cases directly to treatment. The company also noted that some skin cancer cases occurred in patients with prior risk factors.
Importantly, the study reported:
- No deaths
- No cases of acute pancreatitis
- No signs of cardiac fibrosis
- No new safety signals overall
Even so, analysts noted that regulators will likely examine the malignancy findings closely as the review process moves forward.
Market Reaction To Abivax Drug Trial Results
Despite the strong efficacy data, Abivax’s market share fell sharply after the announcement as investors weighed the potential impact of the cancer findings.
Analysts generally agreed that the Abivax bowel disease drug trial demonstrated impressive clinical benefits. The ABTECT maintenance trial delivered strong remission rates, durable disease control, and a favorable overall safety profile, supporting obefazimod’s position as a promising new treatment candidate.
However, many believe additional data will be needed to fully assess whether the reported malignancies represent a meaningful safety concern.
Abivax plans to submit a New Drug Application (NDA) seeking FDA approval for ulcerative colitis in the fourth quarter of 2026. If approved, obefazimod could potentially launch in 2027.
The company is also advancing studies in Crohn’s disease, with topline results expected from an ongoing Phase 2b trial in 2027.
